These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 7645909)

  • 1. Impact of tumour grade, stage, number and size, smoking habits and sex on the recurrence rate and disease-free interval in patients with transitional cell carcinoma of the bladder.
    Raitanen MP; Tammela TL
    Ann Chir Gynaecol; 1995; 84(1):37-41. PubMed ID: 7645909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour.
    Solsona E; Iborra I; Rubio J; Casanova J; Almenar S
    BJU Int; 2004 Dec; 94(9):1258-62. PubMed ID: 15610101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recurrence at three months and high-grade recurrence as prognostic factor of progression in multivariate analysis of T1G2 bladder tumors.
    Palou J; Rodríguez-Rubio F; Millán F; Algaba F; Rodríguez-Faba O; Huguet J; Villavicencio H
    Urology; 2009 Jun; 73(6):1313-7. PubMed ID: 19362341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for local recurrence in patients with pTa/pT1 urinary bladder cancer.
    Jancke G; Damm O; Rosell J; Jahnson S
    Scand J Urol Nephrol; 2008; 42(5):417-21. PubMed ID: 18609266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations.
    Lebret T; Bohin D; Kassardjian Z; Herve JM; Molinie V; Barre P; Lugagne PM; Botto H
    J Urol; 2000 Jan; 163(1):63-7. PubMed ID: 10604315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significant predictive factors for prognosis of primary upper urinary tract cancer after radical nephroureterectomy in Taiwanese patients.
    Li CC; Chang TH; Wu WJ; Ke HL; Huang SP; Tsai PC; Chang SJ; Shen JT; Chou YH; Huang CH
    Eur Urol; 2008 Nov; 54(5):1127-34. PubMed ID: 18243511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years.
    Holmäng S; Hedelin H; Anderström C; Johansson SL
    J Urol; 1995 Jun; 153(6):1823-6; discussion 1826-7. PubMed ID: 7752327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy.
    Yu RJ; Stein JP; Cai J; Miranda G; Groshen S; Skinner DG
    J Urol; 2006 Aug; 176(2):493-8; discussion 498-9. PubMed ID: 16813876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surveillance, initial assessment, and subsequent progress of patients with superficial bladder cancer in a prospective longitudinal study. National Bladder Cancer Collaborative Group A (NBCCGA).
    Cancer Res; 1977 Aug; 37(8 Pt 2):2907-10. PubMed ID: 872120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
    Divrik RT; Yildirim U; Zorlu F; Ozen H
    J Urol; 2006 May; 175(5):1641-4. PubMed ID: 16600720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bladder cancer after managing upper urinary tract transitional cell carcinoma: predictive factors and pathology.
    Raman JD; Ng CK; Boorjian SA; Vaughan ED; Sosa RE; Scherr DS
    BJU Int; 2005 Nov; 96(7):1031-5. PubMed ID: 16225523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for subsequent development of bladder cancer after primary transitional cell carcinoma of the upper urinary tract.
    Matsui Y; Utsunomiya N; Ichioka K; Ueda N; Yoshimura K; Terai A; Arai Y
    Urology; 2005 Feb; 65(2):279-83. PubMed ID: 15708038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The risk factor for urethral recurrence after radical cystectomy in patients with transitional cell carcinoma of the bladder.
    Cho KS; Seo JW; Park SJ; Lee YH; Choi YD; Cho NH; Yang SC; Hong SJ
    Urol Int; 2009; 82(3):306-11. PubMed ID: 19440019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of female non-muscle-invasive bladder cancer in Taiwan: association with upper tract urothelial carcinoma and end-stage renal disease.
    Chen CH; Shun CT; Huang KH; Huang CY; Yu HJ; Pu YS
    Urology; 2008 Jun; 71(6):1155-60. PubMed ID: 18372011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stopping smoking might reduce tumour recurrence in nonmuscle-invasive bladder cancer.
    Chen CH; Shun CT; Huang KH; Huang CY; Tsai YC; Yu HJ; Pu YS
    BJU Int; 2007 Aug; 100(2):281-6; discussion 286. PubMed ID: 17419696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Bladder tumors in young patients].
    Aboutaieb R; Dakir M; Sarrf I; el Moussaoui A; Bennani S; el Mrini M; Meziane F; Benjelloun S
    Prog Urol; 1998 Feb; 8(1):43-6. PubMed ID: 9533150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TUR and adjuvant intravesical chemotherapy in T1G3 bladder tumors: recurrence, progression and survival in 137 selected patients followed up to 20 years.
    Serretta V; Pavone C; Ingargiola GB; Daricello G; Allegro R; Pavone-Macaluso M
    Eur Urol; 2004 Jun; 45(6):730-5; discussion 735-6. PubMed ID: 15149744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ta T1 low and intermediate transitional cell carcinoma of the bladder: recurrence rates and the timing of check cystoscopies within the first year.
    Guney S; Guney N; Canogullari Z; Ergenekon E
    Urol Int; 2008; 80(2):124-8. PubMed ID: 18362479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical panurothelial disease in patients with superficial bladder tumors: therapeutic implications.
    Solsona E; Iborra I; Ricos JV; Monros JL; Rubio J; Almenar S
    J Urol; 2002 May; 167(5):2007-11. PubMed ID: 11956428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer.
    Cheng CW; Chan SF; Chan LW; Chan CK; Ng CF; Cheung HY; Chan SY; Wong WS; Lai FM; To KF; Li ML
    Int J Urol; 2005 May; 12(5):449-55. PubMed ID: 15948743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.